A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806)

Lung Cancer : Journal of the International Association for the Study of Lung Cancer
Sun Min LimJoo-Hang Kim

Abstract

Sorafenib and erlotinib are potent, orally administered receptor tyrosine kinase inhibitors with antiproliferative and antiangiogenic activities. Given their synergistic activity in combination, we conducted a phase II study to determine the clinical activity of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC). Patients with advanced NSCLC who have received one or two prior chemotherapy regimens for metastatic disease, ECOG 0-2, and adequate organ function were eligible. Patients received 400mg twice daily sorafenib and 150 mg daily erlotinib in 28-day cycles. Epidermal growth factor receptor mutation and its downstream pathways were analyzed from available tumor samples. Changes in plasma cytokine and angiogenic factors were correlated with clinical outcomes. A total of 46 patients were enrolled. Twenty patients (43%) were never smokers and 35 patients (75%) had adenocarcinoma histology. The overall response rate was 30.4%. Response to sorafenib/erlotinib was observed more commonly in patients with EGFR mutation than in those with EGFR wild type (WT) or EGFR unknown tumors (62.5% vs. 6.7% vs. 34.8%; P=0.013). Likewise, DCR was higher among patients with EGFR mutation than in ...Continue Reading

References

Jan 11, 2002·The New England Journal of Medicine·Joan H SchillerUNKNOWN Eastern Cooperative Oncology Group
Dec 23, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dirk StrumbergSiegfried Seeber
May 12, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roy S HerbstAlan Sandler
Jun 29, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alex A Adjei, Manuel Hidalgo
Dec 15, 2006·The New England Journal of Medicine·Alan SandlerDavid H Johnson
Jul 3, 2008·Nature Clinical Practice. Oncology·Giampaolo TortoraGiampietro Gasparini
May 19, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·George N NaumovJohn V Heymach
Aug 5, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·George R BlumenscheinMartin Reck
Sep 19, 2009·Expert Review of Anticancer Therapy·Christian ManegoldLothar R Pilz
Sep 3, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Erika MartinelliFortunato Ciardiello
Oct 5, 2010·Cancer Letters·Ilse Roodink, William P J Leenders
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
May 18, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David R SpigelJohn D Hainsworth
May 9, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giorgio V ScagliottiRamaswamy Govindan
May 9, 2014·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Tony MokMartin Reck
Feb 6, 2015·CA: a Cancer Journal for Clinicians·Lindsey A TorreAhmedin Jemal

❮ Previous
Next ❯

Citations

Sep 28, 2016·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Vasileios S SkourasKonstantinos N Syrigos
Sep 18, 2013·Critical Reviews in Oncology/hematology·Audrey Thomas-SchoemannFrançois Goldwasser
Sep 24, 2014·Drug Discovery Today·Djoeke de WitNielka P van Erp
Nov 9, 2020·Critical Reviews in Oncology/hematology·Camille HouronCosmin Sebastian Voican
Oct 17, 2021·Journal of Cellular and Molecular Medicine·Marta Ortega-MuelasRicardo Sánchez-Prieto

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Related Papers

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Ignacio DuranLillian L Siu
Ai zheng = Aizheng = Chinese journal of cancer
Hong-Yun ZhaoLi Zhang
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Alan Sandler, Roy Herbst
Lung Cancer : Journal of the International Association for the Study of Lung Cancer
Jenn-Yu WuPan-Chyr Yang
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Joline S W LindEgbert F Smit
© 2022 Meta ULC. All rights reserved